Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM8074 (Ruxoprubart) in Dermatomyositis
NCT06887738Phase 2Not yet recruiting
- Sponsor
- NovelMed Therapeutics
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ruxoprubart in dermatomyositis (DM), sponsored by NovelMed Therapeutics. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ruxoprubart
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT06887738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887738.